An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard statin therapy, the pill reduced low-density lipoprotein cholesterol, or what ...

Results of the phase 2b PURSUIT study, which evaluated AZD0780 (AstraZeneca), an oral small molecule PCSK9 inhibitor, were presented at the American College of Cardiology Scientific Session.

In addition, AstraZeneca’s experimental cholesterol drug AZD0780 showed promising results in a Phase IIb clinical trial by significantly reducing LDL-C levels in patients. The trial results were ...

Bernstein analyst Florent Cespedes maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £190.00. The ...

Positive results from the PURSUIT phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of ...

At 12 weeks, AZD0780 30mg taken once-daily led to a 50.7% reduction in LDL-C. Similar efficacy was observed regardless of whether trial participants received moderate- or high- intensity statin ...

Upbeat Data From AZN’s Phase II Cholesterol Drug Study AstraZeneca presented positive data from a mid-stage study of its investigational once-daily oral PCSK9 inhibitor, AZD0780, at the annual ...

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol (LDL-C). It acts as a small molecule inhibitor of proprotein ...